Rafferty Asset Management, LLC Biomea Fusion, Inc. Transaction History

Rafferty Asset Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$13.92 - $19.5 $5.24 Million - $7.35 Million	376,688 Added 370.47%	478,367 $7.15 Million
Q4 2023 Feb 13, 2024	SELL	$8.37 - $19.8 $1.11 Million - $2.62 Million	-132,169 Reduced 56.52%	101,679 $1.48 Million
Q3 2023 Nov 13, 2023	BUY	$13.44 - $23.02 $1.3 Million - $2.23 Million	96,945 Added 70.81%	233,848 $3.22 Million
Q2 2023 Aug 11, 2023	BUY	$21.66 - $41.8 $2.97 Million - $5.72 Million	136,903 New	136,903 $3.01 Million

104

17.8M

1.68M

410K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $189M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.